• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Astrotech Corporation (DE) filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    6/3/26 6:01:50 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ASTC alert in real time by email
    astc20260531_8k.htm
    false 0001001907 0001001907 2026-06-02 2026-06-02


    UNITED STATES
     
    SECURITIES AND EXCHANGE COMMISSION
     
    WASHINGTON, DC 20549
     

     
    FORM 8-K
     

     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
     
    Date of report (Date of earliest event reported): June 2, 2026
     

     
    logo.jpg
     
     
    Astrotech Corporation
     
    (Exact Name of Registrant as Specified in Charter)
     
    Delaware
     
    001-34426
     
    91-1273737
    (State or Other Jurisdiction
    of Incorporation)
     
    (Commission
    File Number)
     
    (I.R.S. Employer
    Identification No.)
       
    1817 W. Braker Lane, Suite 400, Austin, Texas
     
    78758
    (Address of Principal Executive Offices)
     
    (Zip Code)
     
    (512) 485-9530
     
    Registrant’s Telephone Number, Including Area Code
     
    (Former Name or Former Address, if Changed Since Last Report)
     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
     
    ☐
    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
    Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
    Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange on which registered
    Common Stock, $0.001 par value per share
     
    ASTC
     
    NASDAQ Stock Market, LLC
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     


     

     
     
    Item 1.01.         Entry into a Material Definitive Agreement.
     
    On June 2, 2026, Astrotech Corporation (the “Company”), entered into an at-the-market offering agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC, as agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time through Wainwright shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $24,492,819 (the “Shares”).
     
    The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-293023) filed by the Company with the Securities and Exchange Commission (the “SEC”) on January 28, 2026 and declared effective by the SEC on January 30, 2026, as supplemented by a prospectus supplement dated June 2, 2026 and filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”).
     
    Pursuant to the Offering Agreement, Wainwright may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act, including sales made by means of ordinary brokers’ transactions, including on The Nasdaq Capital Market, at market prices or as otherwise agreed with Wainwright. Wainwright will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Shares from time to time, based upon instructions from the Company, including any price or size limits or other customary parameters or conditions the Company may impose.
     
    The Company is not obligated to make any sales of the Shares under the Offering Agreement. The offering pursuant to the Offering Agreement will terminate upon the earlier of (i) the issuance and sale of all shares of our common stock subject to the sales agreement, or (ii) the termination of the sales agreement as permitted therein.  
     
    The Company will pay Wainwright a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and has agreed to provide Wainwright with customary indemnification and contribution rights. The Company will also reimburse Wainwright for certain specified expenses in connection with entering into the Offering Agreement. The Offering Agreement contains customary representations and warranties and conditions to the sale of the Shares pursuant thereto.
     
    The foregoing description of the Offering Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.
     
    This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock discussed herein, nor shall there be any offer, solicitation, or sale of common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
     
    Cautionary Statement Regarding Forward-Looking Statements
     
    This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but not are not limited to, statements regarding the ability to sell shares and raise additional funds pursuant to the Offering Agreement.  Such statements involve risks and uncertainties that could cause the Company’s actual results and financial position to differ materially. These risks and uncertainties include uncertainties associated with market conditions and the satisfaction of pre-sale conditions under the Offering Agreement, and other risks described under the heading “Risk Factors” in the Company’s SEC Filings on Form 10-K and Form 10-Q. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date hereof.
     
    Item 9.01.         Financial Statements and Exhibits.
     
    (d) Exhibits
     
    Exhibit
    No.
    Description
    1.1
    At the Market Offering Agreement, dated June 2, 2026, by and between Astrotech Corporation and H.C. Wainwright & Co., LLC
    5.1
    Opinion of Haynes and Boone, LLP
    23.1
    Consent of Haynes and Boone, LLP (included in Exhibit 5.1)
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Date: June 3, 2026
    Astrotech Corporation
     
           
     
    By:
    /s/ Thomas B. Pickens III
     
       
    Name: Thomas B. Pickens III
     
       
    Chief Executive Officer, Chief Technology
    Officer and Chairman of the Board
    (Principal Executive Officer and Principal
    Financial Officer)
     
     
     
    Get the next $ASTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ASTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Becker James Frank bought $19,675 worth of shares (2,034 units at $9.67), increasing direct ownership by 14% to 16,121 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/30/24 9:16:58 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Hinojosa Jaime bought $8,541 worth of shares (900 units at $9.49), increasing direct ownership by 13% to 7,881 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/28/24 9:46:54 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wilkinson Thomas Wiley bought $10,536 worth of shares (1,109 units at $9.50), increasing direct ownership by 6% to 20,862 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/21/24 12:54:36 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Astrotech Corporation Board of Directors Approves Strategic Lunar Resource and Infrastructure Initiative to Advance Future Moon-Based Quantum Computing Manufacturing

    AUSTIN, Texas, May 27, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company"), a science and technology development company with operational spaceflight heritage, today announced that its Board of Directors has approved a strategic initiative focused on lunar resource development, autonomous lunar industrial infrastructure, and future Moon-based advanced computing and semiconductor manufacturing opportunities. The initiative is intended to position Astrotech to evaluate emerging opportunities associated with NASA's Artemis Program, the Commercial Lunar Payload Services ("CLPS") program, and next-generation commercial lunar transportation systems. Astr

    5/27/26 8:30:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EN-SCAN Launches Labrador HH-GC, Engineered to Deliver Laboratory-Grade VOC Analysis Directly in the Field

    AUSTIN, Texas, May 21, 2026 (GLOBE NEWSWIRE) -- EN-SCAN, Inc. ("EN-SCAN"), a subsidiary of Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech"), today announced the commercial launch of the Labrador HH-GC, a rugged, field-portable gas chromatograph engineered to bring laboratory-grade volatile organic compound (VOC) analysis directly to the point of investigation. As environmental regulations tighten and remediation timelines compress, environmental consulting firms and industrial operators are under increasing pressure to identify contamination faster, reduce laboratory delays, and make defensible site decisions in real time. Designed specifically for environmental consultin

    5/21/26 8:30:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech Reports Third Quarter of Fiscal Year 2026 Financial Results

    AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") reported its financial results for the third quarter of fiscal year 2026, which ended March 31, 2026. Financial Highlights & Recent Developments Research and development expense was $554 thousand, a decline of 28% from the third quarter of fiscal year 2026 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect TRACER 1000 product lines.Through March 31, 2026, the Company has deployed the TRACER 1000 trace detection system in approximately 37 locations in 16 countries across the United States, Europe and Asia. "Durin

    5/13/26 8:10:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wilkinson Tom was granted 6,006 shares, increasing direct ownership by 25% to 29,868 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/21/26 4:16:49 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Winn Charles Arch was granted 6,006 shares, increasing direct ownership by 154% to 9,895 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/18/26 8:23:20 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Halinski John William was granted 6,006 shares, increasing direct ownership by 200% to 9,006 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/18/26 8:22:36 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    SEC Filings

    View All

    Astrotech Corporation (DE) filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ASTROTECH Corp (0001001907) (Filer)

    6/3/26 6:01:50 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 424B5 filed by Astrotech Corporation (DE)

    424B5 - ASTROTECH Corp (0001001907) (Filer)

    6/3/26 6:01:20 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Astrotech Corporation (DE)

    10-Q - ASTROTECH Corp (0001001907) (Filer)

    5/13/26 8:30:48 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    Leadership Updates

    Live Leadership Updates

    View All

    Astrotech Reports Second Quarter of Fiscal Year 2026 Financial Results

    AUSTIN, Texas, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") reported its financial results for the second quarter of fiscal year 2026, which ended December 31, 2025. Financial Highlights & Recent Developments Research and development expense was $1,832 thousand, a decline of 25% from the second quarter of fiscal year 2025 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect Tracer 1000 product lines.Through December 31, 2025, the Company has deployed the TRACER 1000 trace detection system in approximately 35 locations in 16 countries across the United States, Europe and As

    2/13/26 8:15:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech Subsidiary 1st Detect Appoints Industry Veteran David Spada as Director of Global Sales to Expand Global Reach of TRACER 1000™

    AUSTIN, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") today announced that its subsidiary, 1st Detect Corporation ("1st Detect"), has appointed industry veteran, David Spada, as Director of Global Sales. This strategic hire strengthens 1st Detect's commercial leadership as the company scales deployment of its TRACER 1000™ mass spectrometry-based explosives and narcotics trace detector across international security markets. Mr. Spada brings over a decade of specialized trace detection experience to the 1st Detect team. Throughout his career at Implant Sciences, Morpho Detection, and Rapiscan Systems, Mr. Spada has held position

    1/21/26 4:15:00 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech Corporation Appoints Scott Bartley as Interim Chief Financial Officer

    AUSTIN, Texas, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or ("Astrotech"), today announced that it has appointed Scott Bartley as Interim Chief Financial Officer ("CFO") of the Company, effective as of October 20, 2025. "We are pleased to announce Scott Bartley as Chief Financial Officer," stated Thomas B. Pickens III, Chairman and Chief Executive Officer of Astrotech Corporation. "He brings over two decades of expertise as a Controller and CFO, across multiple industries, providing important qualification and vantage points for our business across multiple end markets."​Mr. Bartley, age 56, has served as a financial consultant since 2011, inclu

    10/31/25 4:15:00 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    Financials

    Live finance-specific insights

    View All

    Astrotech Announces Listing to the GSA as an Approved United States Government Vendor

    Astrotech Announces Listing to the GSA as an Approved United States Government Vendor AUSTIN, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation (1st Detect), announce that 1st Detect's TRACER 1000TM is now listed in the U.S. General Services Administration (GSA) IT Schedule 70 under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290.   IT Schedule 70 is a long-term contract issued by the GSA to commercial technology vendors that allows sales to the U. S. federal government, one of the largest buyers of goods and services in the world. GSA's thoro

    4/8/24 9:00:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech to Showcase the Tracer 1000 Trace Detector at ISC West Conference

    AUSTIN, Texas, April 02, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation, announces that it will be showcasing its TRACER 1000 Narcotics Trace Detector ("NTD") and Explosives Trace Detector ("ETD") at the International Security Conference and Exposition, also known as ISC West, in Las Vegas, Nevada, from April 9-12, 2024, in booth number 2067. The TRACER 1000 is a high-performance laboratory instrument that is powered by the Astrotech Mass Spectrometer Technology™ ("AMS Technology"). Our mass spectrometer is capable of rapid detection of trace levels of narcotic or explosive compounds in

    4/2/24 9:00:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech Introduces the "Gold Standard" of Mass Spectrometry into Narcotics Detection Market with its State-of-the-Art Tracer 1000

     AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation, announces that it is currently accepting orders for the Tracer 1000 Narcotics Trace Detector (NTD). The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds. Currently, the Company's Tracer 1000 Explosive Trace Detector (ETD) is now found in multiple locations in 14 countries throughout the world. The NTD provides a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo,

    3/25/24 9:00:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Astrotech Corporation (DE)

    SC 13D - ASTROTECH Corp (0001001907) (Subject)

    6/26/23 4:00:53 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Astrotech Corporation (DE) (Amendment)

    SC 13G/A - ASTROTECH Corp (0001001907) (Subject)

    2/8/23 5:29:16 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Astrotech Corporation (DE) (Amendment)

    SC 13G/A - ASTROTECH Corp (0001001907) (Subject)

    2/8/23 4:02:50 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials